Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO

35% response rate in the ADP-A2M4CD8 monotherapy cohort with ~5 months median duration of response in heavily pre-treated patients across a broad range of solid tumors 50% response rate in 26 patients...

Related Keywords

United States ,Philadelphia ,Pennsylvania ,United Kingdom ,Canada ,Julip Miller ,Victor Moreno ,Dana Lynch ,National Cancer Institute Surveillance ,United Newsfile Corp ,Corporate Communications ,Decision Resources Group ,Exchange Commission ,Foundation Inc ,European Society For Medical Oncology ,End Results Program ,Corporate Affairs ,Nasdaq ,Clinical Research ,Annual European Society ,Medical Oncology ,Elliot Norry ,Chief Medical Officer ,Independent Data Safety Monitoring ,Resources Group ,Forecast Aug ,Cancer Institute Surveillance ,Cancer Stat Facts ,Keytruda Prescribing Information ,Clin Oncol ,Prescribing Information ,Keytruda Prescribing ,Opdivo Prescribing ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,Senior Director ,Markets ,